Personalized vancomycin dosing with AI
Deep Learning Based Pharmacokinetic Model for Vancomycin
['FUNDING_R01'] · METHODIST HOSPITAL RESEARCH INSTITUTE · NIH-11159656
Using advanced AI to predict the best vancomycin doses for hospitalized patients so treatment stays effective while lowering side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | METHODIST HOSPITAL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11159656 on ClinicalTrials.gov |
What this research studies
The team will use hospital records of vancomycin doses and blood-level tests from patients like you to train a deep-learning model that learns how individuals process the drug. They will add more detailed patient information (for example, kidney function and other medicines) and use finer timing of doses and labs so the model reflects real care. The AI predictions will be compared to commonly used Bayesian dosing tools to see which gives more accurate blood-level forecasts. The goal is to produce a tool clinicians could use to pick safer, more effective vancomycin doses for each patient.
Who could benefit from this research
Good fit: Hospitalized patients receiving vancomycin with routine blood-level monitoring and recorded dosing in their medical record are the ideal candidates.
Not a fit: People not receiving vancomycin, those without blood-level tests, or patients treated outside participating hospitals are unlikely to benefit directly from this project.
Why it matters
Potential benefit: Could help clinicians choose safer and more effective vancomycin doses tailored to individual patients, potentially reducing kidney toxicity and treatment failures.
How similar studies have performed: Early deep-learning PK models have shown better predictions than standard Bayesian tools in preliminary work, but this approach is still relatively new and being refined.
Where this research is happening
HOUSTON, UNITED STATES
- METHODIST HOSPITAL RESEARCH INSTITUTE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NIGO, MASAYUKI — METHODIST HOSPITAL RESEARCH INSTITUTE
- Study coordinator: NIGO, MASAYUKI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.